Funder: Leukemia & Lymphoma Society (now Blood Cancer United)
Due Dates (Anticipated): January 2027 (Full application) | October 2027 (Letter of intent)
Funding Amounts: Up to $250,000 USD annually for up to three years ($750,000 total), including indirect costs
Summary: Supports translational blood cancer research with appropriate proof of concept and a clear path toward clinical application.
Key Information: Open to independent investigators at nonprofit institutions worldwide; full applications are by invitation only.
Description
The Translational Research Program (TRP), administered by Blood Cancer United, formerly the Leukemia & Lymphoma Society, accelerates promising scientific discoveries toward clinical application in blood cancers. It supports translational projects with potential for near-term clinical impact rather than early-stage discovery research, which is better suited to the funder’s Discovery Grant Program.
Priorities include personalized treatment and novel therapies targeting mutational and epigenetic events in tumor cells and their microenvironment. Areas of interest include aggressive and indolent lymphomas, myeloid and lymphoid disorders, multiple myeloma, and pre-emergent conditions. The program also supports safer and more effective stem cell transplantation, novel immunotherapies, and research on immune synapses relevant to blood cancers. Diseases with high unmet need, including aggressive diseases and those lacking effective therapies, are of particular interest.
